MannKind Responds to Hurricane Harvey Devastation with Afrezza® Donation
September 07 2017 - 9:00AM
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today the
company’s support for Hurricane Harvey victims with a donation of
Afrezza® (insulin human) Inhalation Powder. The donation will be
shipped this week to Insulin for Life USA, Inc., a not-for-profit
entity whose purpose is to aid those living with diabetes by
supplying life-saving insulin and other disease management supplies
in times of need. Insulin for Life USA, Inc., The American Diabetes
Association, and JDRF have partnered to ensure that donated
diabetic supplies get to shelters and county health leaders in the
affected areas as soon as possible.
“In times of crisis, many of us rely on our good health to help
us get to better days,” said Michael Castagna, CEO of MannKind
Corporation. “Among the millions of residents impacted by Hurricane
Harvey are people who must manage their diabetes to maintain good
health – but are separated by circumstance from their supplies.
Extending a helping hand is consistent with our company’s values,
and simply the right thing to do.”
Available through prescription only, Afrezza® is a rapid-acting
inhaled insulin used to improve glycemic control in adults with
diabetes. MannKind has authorized over 27,000 cartridges of insulin
to be donated to Insulin for Life USA. For more information,
including important safety information, on Afrezza®, visit
www.afrezza.com.
“When it comes to rebuilding a life following a major event like
Hurricane Harvey, things rarely go according to schedule,” said
Castagna. “We hope that our support provides some relief to those
in need during such a challenging time.”
About MannKind Corporation MannKind
Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the development
and commercialization of inhaled therapeutic products for patients
with diseases such as diabetes and pulmonary arterial hypertension.
MannKind is currently commercializing Afrezza® (insulin human)
inhalation powder, the Company's first FDA approved product, in the
United States, where it is available by prescription from
pharmacies nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs field
sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.
Company Contact:
Rose Alinaya
SVP, Investor Relations
818-661-5000
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024